Answers are grounded in this paper and cite their sources.
Pancreatic ductal adenocarcinoma (PDAC) remains difficult to treat, and its fibrotic, immunosuppressive tumor microenvironment are major obstacles to chimeric antigen receptor (CAR)-T cell therapy due to the T cell exhaustion and reduction in T cell activation. This proposal asks whether inducible interleukin-18 (IL-18) and biomechanical checkpoint Osr2 knockdown can improve the efficacy of mesothelin-targeted CAR-T cells in PDAC. The proposed CAR-T cell combined split CAR as a "ON" switch which can be integrated by lenalidomide, and inserted with inducible IL-18 cassette and Osr2 shRNA cassette. The drug-dependent CAR provides a method to control the T cell expression which can help reduce the toxicity. Furthermore, IL-18 is intended to support immune activation, while Osr2 shRNA is aimed to knockdown Osr2, in turn, reduce the exhaustion of CAR-T cells associated with the tumor environment. We proposed experiments in different treatments of CAR-T cells including combining a CAR-T cell control group without any modification, CAR-T cell with both modifications, CAR-T cell with only single modification lacking either cassettes, a T-cell group, a mesothelin-negative group, and a vehicle group. By comparing the tumor burden, survival, CAR-T infiltration, exhaustion markers, and toxicity, the results will prove whether "ON" switched CAR-T cells with inducible IL-18 and Osr2 shRNA cassettes can improve the tumor control.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: